Department of Oncology, Dezhou People's Hospital, Dezhou, P.R. China.
Department of Radiology, Dezhou People's Hospital, Dezhou, P.R. China.
J Int Med Res. 2020 Dec;48(12):300060520976824. doi: 10.1177/0300060520976824.
Ovarian cancer remains the most lethal gynecological malignant tumor, with relapse occurring in approximately 70% of advanced cases. Anlotinib is an oral small-molecule multi-targeted tyrosine kinase inhibitor that can resist neoangiogenesis and inhibit tumor growth. Previous research demonstrated clinical antitumor activity of anlotinib in various cancers. We report the case of an elderly woman with advanced ovarian cancer who received anlotinib after failure of multiple-line chemotherapy. A partial response was observed after six cycles of anlotinib monotherapy, with a reduction in the size of the metastases and significantly decreased serum CA125 levels from 1832.7 U/mL to 118.7 U/mL. She continued to take anlotinib, with a progression-free survival time of more than 4 months. Only mild hypertension was observed during the treatment. Anlotinib monotherapy may be a novel therapeutic option for patients with advanced ovarian cancer.
卵巢癌仍然是最致命的妇科恶性肿瘤，约 70%的晚期病例会出现复发。安罗替尼是一种口服小分子多靶点酪氨酸激酶抑制剂，能够抗血管生成并抑制肿瘤生长。先前的研究表明，安罗替尼在多种癌症中具有临床抗肿瘤活性。我们报告了一例老年晚期卵巢癌患者，在多次化疗失败后接受了安罗替尼治疗。在安罗替尼单药治疗的六个周期后观察到部分缓解，转移灶缩小，血清 CA125 水平从 1832.7 U/mL 显著降至 118.7 U/mL。她继续服用安罗替尼，无进展生存期超过 4 个月。在治疗过程中仅观察到轻度高血压。安罗替尼单药治疗可能是晚期卵巢癌患者的一种新的治疗选择。
